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Abstract
Background: Sirtuin1 (SIRT1) regulates gene expression in distinct metabolic pathways and mediates beneficial
effects of caloric restriction in animal models. In humans, SIRT1 genetic variants associate with fasting energy
expenditure. To investigate the relevance of SIRT1 for human metabolism and caloric restriction, we analyzed
SIRT1 genetic variants in respect to the outcome of a controlled lifestyle intervention in Caucasians at risk for
type 2 diabetes.
Methods: A total of 1013 non-diabetic Caucasians from the Tuebingen Family Study (TUEF) were genotyped for
four tagging SIRT1 SNPs (rs730821, rs12413112, rs7069102, rs2273773) for cross-sectional association analyses
with prediabetic traits. SNPs that associated with basal energy expenditure in the TUEF cohort were additionally
analyzed in 196 individuals who underwent a controlled lifestyle intervention (Tuebingen Lifestyle Intervention
Program; TULIP). Multivariate regressions analyses with adjustment for relevant covariates were performed to
detect associations of SIRT1 variants with the changes in anthropometrics, weight, body fat or metabolic
characteristics (blood glucose, insulin sensitivity, insulin secretion and liver fat, measured by magnetic resonance
techniques) after the 9-month follow-up test in the TULIP study.
Results: Minor allele (X/A) carriers of rs12413112 (G/A) had a significantly lower basal energy expenditure (p =
0.04) and an increased respiratory quotient (p = 0.02). This group (rs12413112: X/A) was resistant against
lifestyle-induced improvement of fasting plasma glucose (GG: -2.01%, X/A: 0.53%; p = 0.04), had less increase in
insulin sensitivity (GG: 17.3%, X/A: 9.6%; p = 0.05) and an attenuated decline in liver fat (GG: -38.4%, X/A: -7.5%;
p = 0.01).
Conclusion: SIRT1 plays a role for the individual lifestyle intervention response, possibly owing to decreased
basal energy expenditure and a lower lipid-oxidation rate in rs12413112 X/A allele carriers. SIRT1 genetic variants
may, therefore, represent a relevant determinant for the response rate of individuals undergoing caloric
restriction and increased physical activity.
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The sirtuin SIRT1 (silent mating type information regula-
tion 2 homolog 1) is a NAD+-dependent deacetylase
involved in regulation of glucose metabolism in different
organs [1,2]. SIRT1 directs its deacetylase activity against
histones, a process that facilitates the formation of hetero-
chromatin with subsequent repression of gene transcrip-
tion. In addition, SIRT1 directly regulates activity of
metabolic transcription factors and their co-activators, as
e. g. forkhead transcription factor FOXO1, nuclear factor
NF-κB (nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1) or PGC-1α (peroxisome prolifera-
tor-activated receptor gamma coactivator 1 alpha).
Due to its ubiquitous expression, SIRT1 activity is relevant
for many insulin-sensitive organs. In adipose tissue, SIRT1
down-regulates fat storage by increased lipolysis via the
inactivation of PPARγ (peroxisome proliferator-activated
receptor gamma) [3]. In pancreatic β-cells, SIRT1
enhances glucose-stimulated insulin secretion via down-
regulation of UCP2 (uncoupling protein 2) [4]. In the
liver, particularly under low-nutrient conditions, SIRT1
induces gluconeogenesis and inhibits glycolysis by
deacetylating PGC-1α [5]. In skeletal muscle of obese
mice, SIRT1 mediates the insulin sensitizing effect of res-
veratrol. The antioxidant resveratrol induces increased
exercise endurance and higher basal energy expenditure in
mice, thereby promoting resistance against diet-induced
obesity [6] and mortality [7]. Interestingly, modest over-
expression of SIRT1 also protects mice against high-fat
diet induced glucose intolerance and hepatic steatosis [8],
so that SIRT1 may represent a promising future pharma-
cological target to prevent the metabolic sequelae of
chronic exposure to a high-fat diet.
Summarizing all these data, one may assume that human
SIRT1 genetic variants may also play a role in lifestyle
intervention response in humans. So far, no studies exist
on whether SIRT1 genetic variants affect the individual
metabolic susceptibility to caloric restriction or increased
physical activity. The only genetic study that assessed
SIRT1 genetic variants in the context of metabolism and
diabetes reports an association of SIRT1 genetics with
basal energy expenditure in Finnish type 2 diabetic
patients [6]. We, therefore, conducted the present study to
investigate SIRT1 variants in the context of a controlled
lifestyle intervention in prediabetic individuals at high
risk for later onset of diabetes. For this purpose, 1013 sub-
jects from the cross-sectional Tuebingen Family Study
(TUEF) were genotyped for SIRT1 tagging SNPs and asso-
ciation analyses for energy expenditure and other meta-
bolic traits were undertaken. In a second step, genotypes
that associated with different phenotypes in the TUEF
cohort were analyzed in the ongoing Tübingen Lifestyle
Intervention Programme (TULIP) [9] for longitudinal
changes of blood glucose, insulin secretion, insulin sensi-
tivity and liver fat.
Methods
Study design and participants
All volunteers signed written consent to the study proto-
col, approved by the local medical ethics committee. Gen-
otyping for SIRT1 was done in 1013 study participants, 96
of which were excluded (manifest diabetes or missing
data), resulting in a total cohort of n = 917 for cross-sec-
tional analyses. 196 participants of the study cohort also
participated in TULIP, so that longitudinal (9 month)
data on metabolic traits including liver fat content were
available. TULIP participants are at increased risk of type
2 diabetes (family history of type 2 diabetes, body mass
index (BMI) > 27 kg/m2, diagnosis of IGT or previous
diagnosis of gestational diabetes) and undergo a control-
led lifestyle intervention designed for the same targets as
the Diabetes Prevention Study [10]: body weight reduc-
tion by > 5%, dietary fat (saturated fatty acids) reduction
to < 30% (< 10%) of caloric intake, increase of dietary
fibre (> 15 g/1000 kcal) and enhanced physical activity (>
3 h/week; see [9] for further details on TULIP).
Oral glucose tolerance test (OGTT)
All participants underwent an OGTT performed according
to WHO recommendations [11]. Blood glucose, plasma
insulin, plasma C-peptide and non-esterified fatty acid
(NEFA) levels were determined at 0, 30, 60, 90 and 120
min intervals.
Insulin sensitivity, insulin secretion, and analytical methods
Blood glucose was determined using a bedside glucose
analyzer (Yellow Springs Instruments, Yellow Springs,
CO, USA). Plasma insulin was determined by microparti-
cle enzyme immunoassay (Abbott Laboratories, Tokyo,
Japan), and plasma C-peptide was determined by radio-
immunoassay (Byk-Sangtec, Dietzenbach, Germany).
Insulin sensitivity was estimated using the model from
Matsuda and DeFronzo [12], and insulin secretion was
estimated from 30 min C-peptide levels obtained during
the OGTT. Basal energy expenditure and respiratory quo-
tient were measured with a DELTATRAC™ Metabolic
Monitor (Hoyer; Bremen, Germany) under resting condi-
tions. Further details on analytical procedures are pro-
vided elsewhere [13].
Determination of body and liver fat
Total body fat and lean body mass were measured by bio-
electrical impedance (RJL; Detroit, MI, USA). Liver fat was
determined by magnetic resonance spectroscopy (1.5T
Magnetom Sonata; Siemens, Erlangen, Germany) in the
posterior 7th segment of the liver. A single-voxel stimu-
lated echo acquisition mode technique was applied (rep-
etition time = 4 s, echo time = 10 msec, 32 acquisitions)Page 2 of 7
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culated by the signal integral (methylene/methyl signals
between 0.7–1.5 ppm) in reference to the sum of water
and lipid signal integrals [14].
Genotyping
The TaqMan assay (Eurogentec; Liege, Belgium) and the
fluorescence detecting ABI Prism 7500 (Applied Biosys-
tems; Foster City, CA, USA) were used for genotyping of
SNPs selected by HapMap analysis (phase I, release 21a,
January 2007). A minor allele frequency (MAF) > 0.05 and
a linkage disequilibrium measure (r2) < 0.8 were prereq-
uisites for tagging SNP selection in a region comprising
the whole SIRT1 gene and 10 kb of its promoter. To mon-
itor TaqMan test reproducibility and accuracy, samples of
50 individuals were sequenced for the selected tagging
SNPs with an ABI Prism 310 genetic analyser (Applied
Biosystems). Subsequently, one sample per allelic combi-
nation was included in each TaqMan assay as a known ref-
erence genotype control.
Statistics
Data are presented as means ± SD. The Hardy-Weinberg
equilibrium was calculated by the χ2-test. Multivariate lin-
ear regression analyses with adjustments for relevant cov-
ariates were undertaken, using logarithmically
transformed data for non-normally distributed parame-
ters. The JMP 4.0.4 software (SAS Institute; Cary, NC,
USA) was used for statistical analyses, and p values ≤ 0.05
were considered statistically significant.
Results
SIRT1 genetic variants in the TUEF/TULIP cohort
Four SNPS of the SIRT1 gene (~35 kb, 9 exons) on chro-
mosome 10q21.3 were selected from the HapMap accord-
ing the selection criteria for genotyping: rs730821 (A/G,
MAF = 0.186 in the TUEF cohort, promoter), rs12413112
(G/A, MAF = 0.114, intron4), rs7069102 (G/C, MAF =
0.301, intron4) and rs2273773 (T/C, MAF = 0.058,
intron5). All tagging SNPs were in Hardy-Weinberg-Equi-
librium (p > 0.21; all, both TUEF and TULIP cohort), and
linkage disequilibrium (r2) ranged from 0.008 to 0.53.
Cross-sectional TUEF study
We first verified whether SIRT1 genetic variants associate
with basal energy expenditure in the TUEF cohort, as
shown before in a Finnish population [6]. Indeed, basal
energy expenditure was significantly lower in rs12413112
(p = 0.04; dominant model) and rs7069102 (p = 0.05;
dominant model) minor allele carriers compared to
homozygous carriers of the major G alleles, after adjust-
ment for relevant covariates as age, sex, lean body mass
and body fat [15-17]. Minor allele carriers of rs12413112,
in addition, had a significantly increased respiratory quo-
tient (RQ; +2.2%, p = 0.02; dominant model; see Table 1).
In contrast, anthropometrics (BMI, body fat, waist-to-hip
ratio) did not differ among SIRT1 genotypes. There was
no significant association with (fasting and 2 h OGTT)
glucose and insulin plasma levels, insulin sensitivity
(OGTT and clamped) or insulin secretion (dominant p for
all > 0.12; Table 1). Serum lipid parameters (total-, HDL-
, LDL-cholesterol, apolipoproteins, NEFAs) did also not
differ between SIRT1 genotypes (data not shown).
SIRT1 variants and TULIP lifestyle intervention outcome 
traits
The two SIRT1 SNPs that associated with energy expendi-
ture, namely rs12413112 and rs7069102, were subse-
quently analyzed in 196 individuals (118 females, 78
males, aged 45.8 ± 11.2 years; GG: n = 151, GA: n = 42,
AA: n = 3 individuals) from the TULIP study cohort who
had completed the 9-month follow-up test. In this cohort,
average weight loss amounted to 2.56 ± 4.06 kg in a fol-
low-up time of 259 ± 53 days, resulting in a BMI reduction
of 0.87 ± 1.38.
We did not detect significant associations between
rs12413112 genotype and weight (p = 0.37) or BMI (p =
0.38) change. By contrast, minor allele carriers of
rs12413112 were resistant against lifestyle-induced
improvement of fasting plasma glucose (GG: -2.01%, X/A:
0.53%; p = 0.04, adjusted for age, sex, follow-up time, BMI
at baseline and follow-up and fasting plasma glucose at
baseline; Fig. 1A), had a weaker increase in insulin sensi-
tivity (GG: 17.3%, X/A: 9.6%; p = 0.05, adjusted for age,
sex, follow-up time, BMI at baseline and follow-up and
insulin sensitivity at baseline; Fig. 1B) and a remarkably
attenuated decline in liver fat content (GG: -38.4%, X/A: -
7.5%; p = 0.01, adjusted for age, sex, follow-up time, BMI
at baseline and follow-up and liver fat content at baseline;
Fig. 1C). The effect on liver fat content remained signifi-
cant even after Bonferroni's correction for multiple testing
(2 tests: energy expenditure and obesity), and we had a
power of 0.76 to detect this effect. The rs12413112 geno-
type effects on fasting glucose (0.50) and insulin sensitiv-
ity (0.56) change did not show a sufficient statistical
power and also did not remain significant after correction
for multiple comparisons. The rs7069102 genotype did
not significantly associate with longitudinal changes in
weight (p = 0.40; dominant model), BMI (p = 0.41), fast-
ing glucose (p = 0.08), insulin sensitivity (p = 0.45) and
liver fat (p = 0.09) in the longitudinal TULIP analysis.
Discussion
This is the first study to have analysed the impact of SIRT1
genetic variants on the outcome of a lifestyle intervention
in a diabetes risk population. Despite numerous works
demonstrating SIRT1 function in different insulin-respon-
sive tissues [1,3-5,18,19], we were not able to verify a sig-
nificant association of SIRT1 variants with plasmaPage 3 of 7
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rs2273773 in SIRT1
SNP rs12413112 Genotype Calculation Model
GG GA AA padd pdom prec
n 726 173 18
Sex (men/women), n 266/460 72/101 6/12 0.45a 0.29 0.71
Age (years) 38.6 ± 12.5 38.9 ± 12.8 37.9 ± 13.9 0.92 0.86 0.71
Waist-to-hip ratio 0.87 ± 0.09 0.87 ± 0.09 0.86 ± 0.12 0.69b 0.39 0.80
BMI (kg/m2) 29.3 ± 8.8 29.1 ± 8.0 29.7 ± 8.7 0.08 0.46 0.02
Body fat (%) 30.4 ± 10.9 30.1 ± 11.2 34.0 ± 10.7 0.29 0.53 0.12
Fasting glucose (mmol/l) 5.12 ± 0.66 5.13 ± 0.62 5.07 ± 0.55 0.87c 0.83 0.61
2 h glucose (mmol/l) 6.27 ± 1.73 6.42 ± 1.62 5.84 ± 1.79 0.07 0.42 0.08
Fasting insulin (pmol/l) 64.8 ± 55.1 61.6 ± 47.0 63.5 ± 57.5 0.52 0.35 0.26
2 h insulin (pmol/l) 429 ± 442 441 ± 366 397 ± 337 0.09 0.42 0.29
Insulin sensitivity (AU) 16.6 ± 11.0 15.8 ± 10.7 16.6 ± 8.9 0.19 0.90 0.19
Insulin secretion (pmol/l) 2046 ± 898 2115 ± 907 2172 ± 1054 0.68 0.49 0.53
Basal energy exp (kcal/24 h)d 1730 ± 297 1746 ± 331 1655 ± 292 0.10 0.039 0.31
Respiratory quotientd 0.81 ± 0.07 0.83 ± 0.07 0.81 ± 0.08 0.048 0.017 0.92
rs7069102 GG GC CC
n 457 366 94
Sex (men/women), n 172/285 138/228 34/60 0.96 0.94 0.78
Age (years) 38.2 ± 12.2 39.4 ± 12.8 37.9 ± 13.1 0.36 0.26 0.48
Waist-to-hip ratio 0.86 ± 0.09 0.87 ± 0.09 0.86 ± 0.10 0.84 0.92 0.56
BMI (kg/m2) 29.5 ± 8.9 29.1 ± 8.7 28.8 ± 7.5 0.51 0.48 0.53
Body fat (%) 30.5 ± 11.2 30.2 ± 10.7 30.6 ± 11.4 0.92 0.68 0.88
Fasting glucose (mmol/l) 5.13 ± 0.68 5.12 ± 0.63 5.08 ± 0.55 0.79 0.64 0.65
2 h glucose (mmol/l) 6.27 ± 1.74 6.30 ± 1.64 6.32 ± 1.86 0.94 0.89 0.73
Fasting insulin (pmol/l) 65.2 ± 51.6 63.2 ± 56.6 62.3 ± 52.1 0.73 0.92 0.43
2 h insulin (pmol/l) 441 ± 450 418 ± 401 432 ± 408 0.99 0.89 0.95
Insulin sensitivity (AU) 16.7 ± 11.6 16.2 ± 10.4 16.2 ± 9.9 0.88 0.70 0.67
Insulin secretion (pmol/l) 2091 ± 947 2017 ± 856 2097 ± 866 0.47 0.44 0.44
Basal energy exp (kcal/24 h) 1742 ± 288 1734 ± 334 1680 ± 245 0.06 0.05 0.56
Respiratory quotient 0.81 ± 0.07 0.82 ± 0.07 0.81 ± 0.07 0.35 0.18 0.90
rs730821 AA AG GG
n 603 286 28
Sex (men/women), n 237/366 94/192 13/15 0.11 0.12 0.33
Age (years) 38.4 ± 12.4 39.3 ± 12.9 37.5 ± 13.4 0.59 0.37 0.58
Waist-to-hip ratio 0.87 ± 0.09 0.87 ± 0.09 0.86 ± 0.12 0.38 0.55 0.28
BMI (kg/m2) 29.5 ± 8.7 29.0 ± 8.6 27.7 ± 7.5 0.28 0.12 0.39
Body fat (%) 30.4 ± 11.2 30.5 ± 10.4 27.2 ± 11.3 0.23 0.26 0.13
Fasting glucose (mmol/l) 5.13 ± 0.67 5.11 ± 0.59 5.01 ± 0.66 0.39 0.66 0.22
2 h glucose (mmol/l) 6.28 ± 1.72 6.31 ± 1.66 6.11 ± 2.10 0.34 0.92 0.14
Fasting insulin (pmol/l) 65.1 ± 51.4 61.7 ± 57.5 68.8 ± 61.8 0.55 0.92 0.68Page 4 of 7
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sitivity or insulin secretion, both under fasting conditions
and 2 h OGTT in the cross-sectional analyses. However,
minor allele carriers of rs12413112 had significantly
lower basal energy expenditure and an increased respira-
tory quotient (RQ) at baseline. Interestingly, in a Finnish
population, higher basal energy expenditure was reported
for three SIRT1 SNPs [6]. This difference may be due to the
very low linkage disequilibrium of these three SNPs with
rs12413112, ranging from 0.0076 to 0.10 in both the
TUEF cohort as well as the CEU population of the Hap-
Map project, so that rs12413112 may act in the opposing
direction on SIRT1 function compared to the previously
reported SNPs. In addition, our study cohort has consid-
erably differing allele frequencies compared to the inves-
tigated Finnish population, at least in the SIRT1 locus.
The minor allele of rs12413112 is associated with unre-
sponsiveness of fasting plasma glucose, insulin sensitivity
and liver fat to a controlled 9 month lifestyle intervention.
Because of the higher RQ in this subgroup, one may spec-
ulate that the rs12413112 minor A-allele contributes to a
lower rate of lipid-oxidation, resulting in the observed
lower liver fat reduction, despite dietary changes and
increased physical activity. Taking into account that mod-
est overexpression of SIRT1 leads to protection from high-
fat diet induced hepatic steatosis in mice [8], our study let
assume that the minor allele of rs12413112 may nega-
tively affect SIRT1 expression, especially as the SNPs
tagged by this intronic SNP, namely rs11599151,
rs11599524 and rs12778366, are all located in the SIRT1
promoter.
Finally, the rather small study sample size has to be men-
tioned as the major statistical limitation of this study. The
here reported effects of SIRT1 variants are statistically sig-
nificant, but a conservative adjustment for multiple com-
parisons would render the associations in TUEF with
energy expenditure and RQ non-significant. However, we
think that our findings are relevant, as the TULIP study
provides a very precisely phenotyped and closely moni-
tored lifestyle intervention cohort which is suitable for
studying the role of genetic variants by a classical candi-
date-gene approach.
2 h insulin (pmol/l) 443 ± 440 406 ± 387 433 ± 527 0.62 0.69 0.55
Insulin sensitivity (AU) 16.5 ± 11.5 16.2 ± 9.6 18.1 ± 12.3 0.80 0.82 0.91
Insulin secretion (pmol/l) 2098 ± 945 1997 ± 822 1929 ± 694 0.68 0.38 0.64
Basal energy exp (kcal/24 h) 1746 ± 305 1714 ± 306 1642 ± 217 0.89 0.86 0.63
Respiratory quotient 0.82 ± 0.07 0.81 ± 0.07 0.82 ± 0.08 0.79 0.48 0.88
rs2273773 TT TC CC
n 812 103 2
Sex (men/women), n 313/499 30/73 1/1 0.16 0.07 0.72
Age (years) 38.7 ± 12.4 38.5 ± 13.6 33.0 ± 4.2 0.82 0.80 0.66
Waist-to-hip ratio 0.87 ± 0.09 0.86 ± 0.10 0.77 ± 0.02 0.10 0.68 0.04
BMI (kg/m2) 29.3 ± 8.9 29.2 ± 7.2 24.3 ± 7.1 0.72 0.99 0.42
Body fat (%) 30.2 ± 11.1 31.9 ± 9.7 28.0 ± 18.4 0.78 0.52 0.84
Fasting glucose (mmol/l) 5.13 ± 0.65 5.05 ± 0.62 4.96 ± 0.09 0.19 0.35 0.93
2 h glucose (mmol/l) 6.27 ± 1.71 6.47 ± 1.75 4.58 ± 0.35 0.39 0.31 0.18
Fasting insulin (pmol/l) 63.4 ± 50.5 70.2 ± 74.3 33.0 ± 22.6 0.44 0.61 0.22
2 h insulin (pmol/l) 426 ± 417 470 ± 494 178 ± 212 0.17 0.71 0.06
Insulin sensitivity (AU) 16.5 ± 11.0 15.9 ± 10.1 26.7 ± 14.1 0.38 0.82 0.21
Insulin secretion (pmol/l) 2070 ± 908 2019 ± 864 1299 ± 41 0.45 0.34 0.39
Basal energy exp (kcal/24 h) 1730 ± 304 1756 ± 310 1835 ± 0 0.33 0.16 0.51
Respiratory quotient 0.82 ± 0.07 0.80 ± 0.08 0.84 ± 0 0.19 0.09 0.94
Data are presented as means ± SD; AU, arbitrary units
aAccording to χ2 test; bWaist-to-hip ratio, body mass index (BMI) and body fat were adjusted for age and sex; cAll the following parameters were 
adjusted for age, sex and body fat; insulin secretion was additionally adjusted for insulin sensitivity; dn = 375 participants; basal energy expenditure 
was adjusted to age, sex, lean body mass and body fat.
Table 1: Distribution of anthropometrics and metabolic traits in the TUEF cohort according to rs12413112, rs7069102, rs730821 and 
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Interaction of rs12413112 SIRT1 genotype with the metabolic responses during a controlled 9-month lifestyle interventionFigure 1
Interaction of rs12413112 SIRT1 genotype with the metabolic responses during a controlled 9-month lifestyle 
intervention. Rs12413112 SIRT1 genotype (GG): filled circles (●); X/A: opened circles (❍). a) Response of plasma glucose 
determined during the fasting state. b) Response of insulin sensitivity estimated by the formula from Matsuda et al. [12]. c) 
Response of liver fat content, determined by magnetic resonance spectroscopy. For statistical analyses, all data were log-trans-
formed and adjusted for age, sex, follow-up-time, BMI at both baseline and follow-up and the corresponding variable (plasma 
glucose, insulin sensitivity or liver fat) measured at baseline. Data are presented as means+SEM (G/G: n = 152, X/A: n = 45 
TULIP participants).
BMC Medical Genetics 2008, 9:100 http://www.biomedcentral.com/1471-2350/9/100Conclusion
In summary, our study shows that SIRT1 genetic variants
may affect individual susceptibility to caloric restriction
and increased physical activity. Although the cross-sec-
tional study let rather doubt that SIRT1 does represent a
classical diabetes risk gene, SIRT1 genetic variants may
determine the individual response to a lifestyle interven-
tion. Beyond AdipoR1 [14] and PPARδ [20], SIRT1 is the
third gene detected which does not affect prediabetic traits
in a cross-sectional study approach, but which remarkably
influences the response to a lifestyle intervention. There-
fore, SIRT1 should be elucidated in other prospective life-
style intervention studies, and further research on SIRT1
as a potential pharmacological target for prevention of
type 2 diabetes is warranted.
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